Asston Pharmaceuticals IPO Receives 40 Times Subscription Applications by Start of Day 3

Mumbai, 11 July 2025: Asston Pharmaceuticals’ IPO continues to witness robust interest on Day 3, with the overall subscription reaching 40.01 times as of 11:54 AM. Led by aggressive bidding from retail and non-institutional investors, the issue has garnered widespread participation ahead of its scheduled close later today.

Retail Investors Oversubscribe Their Quota Nearly 47 Times

The retail investor category saw enthusiastic participation, with subscriptions reaching 46.72 times. Investors in this category were required to apply for a minimum of two lots (2,000 shares), translating to an investment of ₹2,46,000. The high subscription level from individual investors signals strong confidence in Asston’s fundamentals and business outlook.

High Net-Worth Individuals Drive NII Bidding Beyond 66 Times

The Non-Institutional Investor (NII) category was the most subscribed, reaching 66.21 times. Within this, the bNII subcategory (applications above ₹10 lakh) was subscribed a remarkable 72.27 times, while the sNII subcategory (below ₹10 lakh) saw 55.08 times subscription. The intense bidding suggests that HNIs are optimistic about the company’s future performance and listing prospects.

QIB Interest Strengthens to Over 8 Times

Qualified Institutional Buyers (QIBs) recorded a subscription of 8.36 times so far. Although QIB interest tends to peak closer to the end of the issue period, the increasing demand reflects a favourable assessment of Asston Pharmaceuticals by institutional investors.

Anchor and Market Maker Portions Fully Subscribed

Prior to the public bidding, anchor investors fully subscribed to their allocated 6.35 lakh shares, bringing in ₹7.81 crore. Similarly, the market maker-JSK Securities and Services Pvt Ltd-took up the committed 1.13 lakh shares. These early commitments provided initial momentum and stability to the IPO process.

IPO Structure and Key Details

Asston Pharmaceuticals IPO is a fresh issue of 22.41 lakh shares, aggregating up to ₹27.56 crore. The offer is being made through the book-building route, with the price fixed at ₹123 per share. The IPO includes:

• A retail allocation of 7.46 lakh shares
• NII portion of 3.22 lakh shares
• QIB quota of 4.25 lakh shares
• Anchor investor allotment of 6.35 lakh shares
• Market maker portion of 1.13 lakh shares

The lot size is 1,000 shares. For HNIs, the minimum application size is 3 lots (3,000 shares) worth ₹3,69,000.

About the Company: Export-Focused Pharmaceutical Manufacturer

Asston Pharmaceuticals is engaged in manufacturing and exporting a wide range of healthcare products, including tablets, syrups, capsules, and sachets across various therapeutic categories such as antibiotics, antifungals, analgesics, and nutritional supplements. The company operates under both direct sales and contract manufacturing models, following a principle-to-principle business structure with multiple marketing partners.

Certified by the Central and State FDA, accredited by NQA, and compliant with Quality Management System (QMS) standards, Asston’s manufacturing operations are aligned with stringent global quality protocols.

Proposed Use of IPO Proceeds

The net proceeds from the IPO are earmarked for the following purposes:

• ₹6 crore for the acquisition of new machinery at the manufacturing unit
• ₹13 crore to support working capital requirements
• ₹1 crore for partial repayment or prepayment of outstanding borrowings
• Balance funds to be used for general corporate purposes

Next Steps: Allotment and Listing Timeline

The IPO will close later today, and the basis of allotment is expected to be finalised by Monday, 14 July 2025. Shares are likely to be credited to investors’ demat accounts ahead of the tentative listing on BSE SME scheduled for Wednesday, 16 July 2025.

Sobhagya Capital Options Ltd is managing the issue as the book-running lead manager, while Maashitla Securities Pvt Ltd serves as the registrar.

With strong oversubscription across all investor segments and a robust business model, Asston Pharmaceuticals appears set for a promising market debut.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations